Please login to the form below

Not currently logged in
Email:
Password:

companion diagnostic

This page shows the latest companion diagnostic news and features for those working in and with pharma, biotech and healthcare.

Loxo, Bayer get FDA okay for biomarker-driven cancer drug

Loxo, Bayer get FDA okay for biomarker-driven cancer drug

At the moment there is no companion diagnostic for NTRK fusions so patients need to be identified through genomic profiling techniques such as immunohistochemistry or genetic sequencing approaches, which tend to ... To try to address the diagnostic issue,

Latest news

More from news
Approximately 1 fully matching, plus 53 partially matching documents found.

Latest Intelligence

  • Harnessing complexity Harnessing complexity

    This delicate balance between companion diagnostics' clinical utility and their potential confounding impact on patient treatment is a growing dilemma. ... Answering this question in full requires a scientific journey to better understand what a

  • Diagnostics are rising up the pharma value chain Diagnostics are rising up the pharma value chain

    Diagnostic drivers. It's not just this idea of changing public attitudes that is creating renewed interest in the diagnostics sector; the sector is also influenced by the wider forces affecting ... GlaxoSmithKline and Boehringer Ingelheim have had

  • Deal Watch table for June 2014 Deal Watch table for June 2014

    50. NanoString Technologies/ Celgene. Development. Development of a companion diagnostic assay.

  • Pharma deals during June 2014 Pharma deals during June 2014

    a deal with NanoString Technologies for the development of a companion diagnostic assay to support the development of Revlimid for treatment of Diffuse Large B-Cell Lymphoma at a more modest

  • Interview: John Dineen, GE Healthcare Interview: John Dineen, GE Healthcare

    some of these markers can be converted into a companion diagnostic product after the completion of a late-stage clinical trial. ... We can then ensure our diagnostic is closely coupled with the therapeutic capability.

More from intelligence
Approximately 0 fully matching, plus 5 partially matching documents found.

Latest from PMHub

  • Mastering the precision medicine opportunity

    Novartis and Roche are two champions of personalised medicine, shaping the area with the launch of targeted treatments combined with a companion diagnostic to support patient identification. ... approval of their new  FoundationOne CDx, the first and

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
OUTiCO

Providing an exceptional outsourcing service to the Pharma & Healthcare industries. We offer a sustainable approach and drive sales outcomes...

Latest intelligence

Alzheimer’s disease – is Europe prepared if a breakthrough treatment becomes available?
Healthcare leaders in the European Union should begin preparing for a breakthrough now...
The UK’s new five-year pricing agreement
Pharma has agreed to capped growth again - in exchange for uptake promises...
Digital applications are transforming the market access landscape
Organisations are leveraging new technology to implement a wider range of business models and, in essence, drive market access success by working smarter, faster and with greater economy....

Infographics